High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Oura Inc. is pitching its U.S. initial public offering to investors, aiming for a fully diluted value of about $15.62 billion as it sizes up demand for consumer tech deals. The smart-ring maker plans to price next week, as markets...
Smart ring maker Oura is seeking a valuation of as much as $15.6 billion in an IPO that could test investor appetite for a new wave of fall listings.
Oura, a smart ring maker, said Monday it launched a US initial public offering of 50 million common
Oura is offering 50 million shares at $40 to $44 each, targeting a fully diluted valuation of $15.62 billion
Oura, the Finnish maker of smart health-tracking rings, disclosed plans on Monday to sell 50 million shares priced between $40 and $44 each in its initial public offering. The offering could raise as much as $2.2 billion and value the company at up to $14.1 billion based on its outstanding...
Investing.com -- Oura is seeking to offer 50 million shares priced between $40 and $44 each, the company disclosed in a Monday SEC filing. The smart ring maker plans to offer 13.5 million shares, while existing stockholders will sell 36.5 million shares.
The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.
The drug giant added to its immunotherapy portfolio.
Lilly also announced that combining its inflammation treatment Taltz with Zepbound delivered lasting improvements in adults with psoriasis or psoriatic arthritis who were obese in two late trials.
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
Strong demand helps the Lilly-backed biotech raise nearly $129 million
Gene-editing biotech targets up to $242.7 million valuation, with initial ASCVD trial data expected in 2027.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by...
Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.
Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.
Investing.com -- Elon Musk’s SpaceX on Thursday said that it has priced its initial public offering at $135 per share on Thursday, raising $75 billion in the largest IPO in U.S. history.
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
Infectious disease could fuel Eli Lilly's next growth phase.
Eli Lilly agreed to buy three vaccine developers targeting shingles, bacterial infections and Epstein-Barr Virus.
Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease...
Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.
Eli Lilly announced deals to acquire three biotechnology companies, Curevo, LimmaTech Biologics, and Vaccine Company for roughly $3.8 billion in total consideration.
The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs
The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
